Interesting read about another company that is apparently researching anti biotics with similar mode of activity. Interesting that they are effective against gram negative and ESKAPE pathogens. Receiving lots of funds from this carb x group. It seems to specifically state they are not effective against gram positive so a great advantage for rce there.
Polyphor also presented data from different studies on its new medium-spectrum antibiotic POL7306 from its OMPTA class with a novel mechanism of action, which is in preclinical development for the treatment of infections caused by antimicrobial resistant Gram-negative bacteria. Results demonstrated that POL7306 shows a potent activity against a large collection of Gram-negative organisms collected worldwide that include colistin-resistant, extensively drug-resistant, and extended spectrum beta-lactamase- and carbapenemase-producing isolated for which there are currently limited treatment options. The spectrum of activity includes all Gram negative ESKAPE** and WHO priority 1 Gram-negative pathogens**. In addition, POL7306 demonstrated potent in vivo activity and has shown a low propensity of resistance development.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)